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Introduction: Inflammatory cytokines play a key role in the pathogenesis of joint diseases such as rheumatoid
arthritis (RA). Current therapies target mainly tumor necrosis factor α (TNF-α) as this has proven benefits. However, a
large number of patients do not respond to or become resistant to anti-TNF-α therapy. While the role of TNF-α in
RA is quite evident, the role of TNF-β, also called lymphotoxin-α (LT-α), is unclear. In this study we investigated
whether TNF-β and its receptor play a role in chondrocytes in the inflammatory environment.
Methods: An in vitro model of primary human chondrocytes was used to study TNF-β-mediated inflammatory
signaling.
Results: Cytokine-induced inflammation enhances TNF-β and TNF-β-receptor expression in primary human
chondrocytes accompanied by the up-regulation of inflammatory (cyclooxygenase-2), matrix degrading
(matrix metalloproteinase-9 and -13) and apoptotic (p53, cleaved caspase-3) signaling pathways, all known to be
regulated by NF-κB. In contrast, anti-TNF-β, similar to the natural NF-κB inhibitor (curcumin, diferuloylmethane) or
the knockdown of NF-κB by using antisense oligonucleotides (ASO), suppressed IL-1β-induced NF-κB activation and
its translocation to the nucleus, and abolished the pro-inflammatory and apoptotic effects of IL-1β. This highlights,
at least in part, the crucial role of NF-κB in TNF-β-induced-inflammation in cartilage, similar to that expected for
TNF-α. Finally, the adhesiveness between TNF-β-expressing T-lymphocytes and the responding chondrocytes was
significantly enhanced through a TNF-β-induced inflammatory microenvironment.
Conclusions: These results suggest for the first time that TNF-β is involved in microenvironment inflammation
in chondrocytes during RA parallel to TNF-α, resulting in the up-regulation of NF-κB signaling and activation of
pro-inflammatory activity.Introduction
In 1984, one of our groups isolated two different cyto-
kines, tumor necrosis factor α (TNF-α) and TNF-β, from
macrophages and lymphocytes, respectively [1]. When we
examined them for their receptors, we found that both
cytokines bind to the same receptor [2]. Although the role
of TNF-α in a wide variety of diseases, including rheuma-
toid arthritis (RA), is very well-documented, very little is
known about TNF-β. Recent evidence suggests that TNF-β,
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reproduction in any medium, provided the orsuperfamily, may play a critical role in RA [3]. TNF-β
shows 35% identity and 50% homology to TNF-α at amino
acid sequences, making it the closest homolog to TNF-α
and shows further structural similarity in tertiary and
quaternary structure, indicating similar biological activity
[2,4]. TNF-β is expressed by a variety of cells, including
T cells, B cells and natural killer (NK) cells [5]. TNF-β can
be secreted and, like TNF-α, binds with high affinity to
TNF receptors 1 and 2 (TNFR-1 and TNFR-2) [4], and it
is transiently expressed on the cell surfaces of activated B
and T cells, where it forms a complex with LT-β as an
LTα1β2 heterotrimer [6,7]. Recent evidence indicates that,
for some physiological processes, TNF and LTαβ work to-
gether as components of an integrated signaling networktral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and ligands [7].
RA is a chronic, systemic inflammatory autoimmune
disease characterized by inflammation of the synovial
joints [8]. Because of its persistent inflammatory environ-
ment, RA is accompanied by progressive joint degene-
ration, with pain and impairment of patients’ daily lives.
Hallmarks of RA are enhanced proliferation of fibroblast-
like synoviocytes (FLSs) accompanied by an increase in
proinflammatory cytokines such as interleukin 1 (IL-1),
IL-6 and TNF-α [9,10].
IL-1β is a well-studied mediator of cartilage destruction
in osteoarthritis (OA) and RA. This mediating effect
occurs by reducing chondrocyte proteoglycan synthesis,
increasing synthesis of matrix metalloproteinases (MMPs)
and releasing nitric oxide [11,12]. IL-6 is known to en-
hance inflammation through its action on T and B cells as
well as monocytes and neutrophils, and it is involved in
the activation of osteoclasts [13]. TNF-α, first discovered
as an anticancer agent, is known to contribute to host
defense against infection, but it is also involved in the
pathogenesis of many diseases and plays a key role in
stimulating the inflammatory response in RA, which leads
to synovial proliferation as well as bone and cartilage
destruction [5].
Current treatment regimens for RA often target a spe-
cific cytokine to suppress inflammatory processes [14-17].
Because TNF-α plays a major role in promoting RA, its in-
hibition has been used for the treatment of RA with very
promising results [12,18]. Unfortunately, it has recently
been shown that many patients do not, or only slightly,
respond to anti-TNF-α therapy and that up to 50% of
patients become resistant to TNF-α therapy after five
years of treatment [19]. Furthermore, TNF-α therapy is
implicated in the increased risk of serious infections and
malignancies [20]. This set of problems demonstrates a
necessity for additional efficacious and safe alternative
therapies for RA.
Previous studies have indicated that TNF-β levels are
elevated in the serum and synovial tissue of RA and OA
patients [21-23]. A recent report demonstrated that TNF-β
stimulates proliferation and inflammatory cascade sig-
naling in FLSs, which is a trigger and initial starting point
of RA [3]. Interestingly, in an in vivo collagen-induced
arthritis mouse model, anti-TNF-β therapy dramatically
improved the disease course comparably to anti-TNF-α
therapy [24]. Recently, pateclizumab, a TNF-β antibody,
has been evaluated in a phase I clinical trial with good
tolerance [25].
For safe and effective therapeutic use, however, more
detailed information on the role of TNF-β in RA is
needed. This is especially true regarding the interaction
between chondrocytes, as the major architects of func-
tional joint tissue, and TNF-β, which should be evaluatedin more detail to better understand the inflammatory and
degradative processes of RA.
In the search for effective and safe RA therapies, natural
compounds have also shown ability to suppress inflam-
matory processes through inhibition of TNF-α. Curcumin
(diferuloylmethane), when isolated from the rhizomes of
Curcuma longa, has strong anti-TNF-α activity and can
further suppress TNF-α production through inhibition
of nuclear factor κB (NF-κB) activation [26-28]. Also,
in chondrocytes, curcumin inhibits inflammation and
matrix degradation by suppressing NF-κB activation
[28,29]. Antisense oligonucleotides (ASOs) have been re-
ported to selectively downregulate the translation of sub-
cellular target genes [30,31]. ASO-based chemicals have
been developed as gene-silencing therapeutic agents for
use in clinical trials, such as cancer studies [32,33].
Therefore, because an increasing body of evidence sug-
gests that TNF-β may play a major role in an inflamma-
tory joint environment, we decided to find out whether
TNF-β and its receptor are expressed by primary human
chondrocytes in an in vitro model of RA and to investigate
the underlying signaling pathways.Methods
Antibodies
Antibodies to active caspase 3, MMP-9 and MMP-13 were
purchased from R&D Systems (Heidelberg, Germany).
Anti-phospho-specific p65 (NF-κB/Ser536) was obtained
from Cell Signaling Technology (Beverly, MA, USA). Anti-
TNF-β, anti-TNF-α and anti-TNF-β receptor (anti-TNF-
β-R) antibodies were obtained from eBioscience (Frankfurt,
Germany). Monoclonal poly(ADP-ribose) polymerase
(PARP) antibodies were purchased from Becton Dickin-
son (Heidelberg, Germany). Cyclooxygenase 2 (Cox-2)
antibody was obtained from Cayman Chemical (Ann
Arbor, MI, USA). Monoclonal anti-β-actin antibody
was purchased from Sigma-Aldrich Chemie (Munich,
Germany). Antibodies against p53 were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Alkaline phosphatase–linked sheep anti-mouse and sheep
anti-rabbit secondary antibodies for immunoblotting were
purchased from EMD Millipore (Schwalbach, Germany).
Secondary antibodies used for fluorescence labeling were
purchased from Dianova (Hamburg, Germany). Gold par-
ticle–conjugated secondary antibodies were purchased
from Amersham (Braunschweig, Germany). All antibodies
were used at concentrations recommended by the manu-
facturers. TNF-β and polyclonal rabbit anti-TNF-β anti-
bodies were used as described previously [34] and were
kindly provided by BB Aggarwal (The University of Texas
MD Anderson Cancer Center, Houston, TX, USA).
Bacteria-derived recombinant human TNF and LT, both
purified to homogeneity with a specific activity of 50
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San Francisco, CA, USA).Growth media, chemicals and cytokines
Cell culture growth medium consisting of Dulbecco’s
modified Eagle’s medium/Ham’s F-12 (1:1), 10% fetal
bovine serum (FBS), 1% partricin solution, 1% penicillin-
streptomycin solution (10,000 IU/10,000 IU), 75 μg/ml
ascorbic acid, 1% essential amino acids and 1% glutamine
was obtained from Seromed (Munich, Germany). Epon
was obtained from Plano (Marburg, Germany). Curcumin
with a purity greater than 95% was purchased from Indsaff
(Punjab, India) and dissolved in dimethyl sulfoxide, and a
5,000 μM stock was prepared and further diluted in cell
culture medium. This commercial source of curcumin
contains three major components: diferuloylmethane (the
most abundant and active component of turmeric) (82%)
and its derivatives demethoxycurcumin (15%) and bisde-
methoxycurcumin (3%), together referred to as curcumi-
noids [35,36]. IL-1β was purchased from Acris Antibodies
GmbH (Herold, Germany).Chondrocyte and T lymphocyte culture
Primary human chondrocytes (catalog no. 121 0211)
were obtained from Provitro (Berlin, Germany). Briefly,
during monolayer expansion, chondrocytes were seeded
at a density of 300,000 cells/T75 cell culture flask and
grown until 70% confluence was reached in cell culture
growth medium (10% FBS) [37]. Chondrocytes were
passaged up to two times, and passages 2 and 3 were
used in the experiments. Chondrocytes were washed
three times with serum-starved medium (containing
only 3% FBS) and further incubated for 30 minutes with
the same medium before initiation of treatment with
TNF-β and/or inhibitors. Cartilage samples were de-
rived from patients, who provided their full informed
consent. Local ethics committee approval was provi-
ded by the Charité-University Medical School Berlin,
Germany. A human T lymphocyte cell line (Jurkat cells)
[38] was cultured in suspension with whole-cell culture
growth medium.Time- and concentration-dependent experiments
To evaluate the effect of IL-1β on TNF-β expression
in primary human chondrocytes, time- and dose-
dependent experiments were carried out. Primary hu-
man chondrocytes in monolayer culture were either left
untreated or treated with 10 ng/ml IL-1β for various du-
rations (5, 10, 20, 40 or 60 minutes) or with various con-
centrations of IL-1β (0, 10, 15, 20 or 25 ng/ml) for
1 hour. Whole-cell extracts were prepared, and im-
munoblotting was carried out as described below.Antisense and Lipofectin-mediated transfection in
chondrocytes
Transient transfection of primary human chondrocytes
was performed as previously described [39]. Phospho-
rothioate-specific oligonucleotides (21-mer) in ASOs
(sequence 5′-GAGATGCGCACTGTCCCTGGTC-3′) cor-
responding to NF-κB/p65 subunit mRNA and control
21-mer sense oligonucleotides (SOs) (sequence 5′-GAC
CAGGGACAGTGCGCATCTC-3′) used in the expe-
riments were synthesized by Eurofins MWG Operon
(Ebersberg, Germany). All ASOs and SOs were phos-
phorothioate-modified to protect them from the cell nu-
cleases. Transfection was carried out by incubating the
primary chondrocytes in monolayer culture for 24 hours
with 0.5 μM ASO against NF-κB or SO control and
10 μl/ml Lipofectin transfection reagent (Invitrogen,
Carlsbad, CA, USA) in serum-starved medium (3% FBS)
before starting the respective experiments. All transfec-
tion experiments were carried out on 50% confluent
monolayer cultures.
Western blot analysis and immunoblotting
Whole-cell lysates or nuclear extracts used for Western
blot analysis were prepared as previously described in
detail [40,41]. Briefly, for whole-cell extracts, proteins
were extracted with lysis buffer (50 mM Tris–HCl,
pH 7.2, 150 mM NaCl, 1% (v/v) Triton X-100, 1 mM
sodium orthovanadate, 50 mM sodium pyrophosphate,
100 mM sodium fluoride, 0.01% (v/v) aprotinin, 4 μg/ml
pepstatin A, 10 μg/ml leupeptin, 1 mM phenylmethylsul-
fonyl fluoride) on ice for 30 minutes. For nuclear extracts,
chondrocytes were trypsinized and washed twice in 1 ml
of ice-cold phosphate-buffered saline (PBS). The cell pellet
was resuspended in 400 μl of hypotonic lysis buffer
containing protease inhibitors and incubated on ice for
15 minutes. Next, 12.5 μl of 10% Nonidet P-40 were
added, and the cell suspension was vigorously mixed for
15 seconds. The extracts were centrifuged for 1.5 minutes
at 14,000 × g. The supernatants (cytoplasmic extracts)
were frozen at −80°C. Ice-cold nuclear extraction buffer
(25 μl) was added to the pellets and incubated for
30 minutes with intermittent mixing. Extracts were cen-
trifuged, and the supernatant (nuclear extracts) was trans-
ferred to the prechilled tubes for storage at −80°C. Total
protein content was measured, samples were reduced with
2-mercaptoethanol and total protein concentrations were
adjusted. After separation with SDS-PAGE under reducing
conditions, the resultant was blotted onto a membrane
using a Trans-Blot apparatus (Bio-Rad Laboratories,
Hercules, CA, USA) and blocked for 2 hours in 5%
(w/v) skimmed milk powder in PBS/0.1% Tween 20.
Membranes were incubated overnight with the primary
antibody directed against TNF-β, TNF-α, MMP-9
and −13, Cox-2, p53, cleaved caspase 3, NF-κB-p65,
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blocking buffer at 4°C on a shaker, washed three times
with blocking buffer, then incubated with the secon-
dary antibody conjugated with alkaline phosphatase for
90 minutes at ambient temperature (AT). Membranes
were washed three times in 0.1 M Tris (pH 9.5) con-
taining 0.05 M MgCl2 and 0.1 M NaCl. Specific anti-
gen–antibody complexes were detected using nitroblue
tetrazolium and 5-bromo-4-chloro-3-indoylphosphate
(p-toluidine salt; Pierce Biotechnology, Ulm, Germany)
as substrates for alkaline phosphatase.
Immunofluorescence analysis of TNF-β, TNF-β-R and
NF-κB
The technique was performed as previously described in
detail [29]. Briefly, primary human chondrocytes were cul-
tured until 50% confluence was reached on four-well
chamber slides or glass plates treated for the different ex-
periments and fixated with methanol at AT for 10 minutes.
Cells were rinsed three times with PBS and overlaid with
bovine serum albumin (BSA) at AT. Primary antibodies
(TNF-β, TNF-β-R and NF-κB (1:50) in PBS/BSA) incu-
bation was performed overnight at 4°C in a humidified
chamber, followed by incubation with rhodamine-coupled
secondary antibodies (diluted 1:80 in PBS) for 1 hour at
AT and washed again three times with aqua dest (that is,
distilled) laboratory water. Counterstaining was performed
with 4′,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich
Chemie) to visualize cell nuclei. The slides were then
covered with fluoromount mountant and examined under
a fluorescence microscope (Leica Microsystems, Wetzlar,
Germany).
Immunoelectron microscopy (preembedding technique)
Detection of TNF-β-R expression on T lymphocytes
(Jurkat cells) by immunoelectron microscopy was per-
formed as previously described [42]. Jurkat cells were
treated with anti-TNF-β-R for 10 minutes at a concentra-
tion of 1:20 in cell culture medium, followed by treatment
with 10 nanometer goat anti-rabbit gold-conjugated sec-
ondary antibodies for an additional 10 minutes at AT
(diluted 1:30 in growth medium). Cells were fixed with 2%
glutaraldehyde for 5 minutes and postfixed in 1% OsO4
solution. After dehydration in a series of ethanol washes,
pellets were embedded in Epon and ultrathin cuts were
made on a Reichert-Jung Ultracut E microtome (Leica
Microsystems) and contrasted with a mixture of 2% uranyl
acetate/lead citrate. Sections were examined under a Zeiss
10 transmission electron microscope (Institute of Pharma-
cology, Berlin, Germany).
Adhesion assay interaction of chondrocytes with T cells
Primary human chondrocytes were grown to subconfluence
in a monolayer culture and either left unstimulated orstimulated with 1 or 10 ng/ml TNF-β for 12 hours,
washed and then cocultured with T lymphocytes (Jurkat
cells) (2 × 106/ml) for 4 hours. Subsequently, nonadherent
T cells were removed by gentle washing three times with
PBS before paraformaldehyde fixation for evaluation by
light microscopy.
Results
The aim of the present study was to evaluate the poten-
tial inflammatory and apoptotic signaling role of TNF-β
(alias LT-α) in an in vitro model of IL-1β-induced in-
flammatory environment, such as RA in primary human
chondrocytes. Furthermore, we evaluated signaling inter-
actions between TNF-β and the NF-κB pathway, as well
as the potential beneficial role of curcumin in suppres-
sing TNF-β-induced gene products that lead to inflam-
mation, degradation and apoptosis. We purposely chose
to stimulate the inflammatory reaction in the chondro-
cytes with IL-1β instead of TNF-α to avoid any possible
cross-reactions between TNF-β and TNF-α signaling.
IL-1β induces TNF-β and TNF-β-R expression in human
chondrocytes
Because it is unknown whether healthy or inflamed
chondrocytes express TNF-β or TNF-β-R, we evaluated
whether IL-1β stimulates chondrocytes to express TNF-
β and TNF-β-R. Primary human chondrocytes in mono-
layer cultures were either left untreated (Figure 1A and
1E: control (CO.), without primary antibody; Figure 1B
and 1F: basal control (Basal CO.), with primary anti-
body) or stimulated with 1 ng/ml IL-1β (Figure 1C and
1G) or 5 ng/ml IL-1β (Figure 1D and 1H) for 1 hour
and subjected to immunolabeling with anti-TNF-β or
anti-TNF-β-R and rhodamine-coupled secondary anti-
bodies. DAPI counterstaining was performed to visualize
cell nuclei. We found that untreated chondrocytes had
low basal expression of TNF-β (Figure 1B) and TNF-β-R
(Figure 1F). However, inflammatory stimulation with
IL-1β markedly induced TNF-β and TNF-β-R expression
in chondrocytes at both at 1 and 5 ng/ml concentrations
(Figure 1C, 1D, 1G and 1H).
IL-1β induces TNF-β protein in a dose- and
time-dependent manner in human chondrocytes
We next examined whether the observed IL-1β-induced
expression of TNF-β in primary human chondrocytes
was time- and dose-dependent. Primary human chon-
drocytes were either treated with 10 ng/ml IL-1β for the
indicated time points (Figure 2A) or treated with various
concentrations of IL-1β for 1 hour (Figure 2B). Immuno-
blotting of whole-cell extracts shows a time-dependent
increase in TNF-β expression in chondrocytes during
IL-1β treatment, reaching a maximum production level
of TNF-β after 10 minutes (Figure 2A). Moreover, we
Figure 1 Detection of TNF-β and TNF-β receptor expression in cultured human chondrocytes in vitro by immunofluorescence
microscopy. Primary human chondrocytes were either left untreated (Co. (A) and (E): without primary antibody; basal-co.: (B)) and (F) with
primary antibody) or treated for 1 hour with 1 ng/ml interleukin 1β (IL-1β) (C) and (G) or 5 ng/ml IL-1β (D) and (H). Immunolabeling was per-
formed with primary antibodies for tumor necrosis factor β (TNF-β) (B) through (D) and TNF-β receptor (TNF-β-R) (E) through (H), followed by in-
cubation with rhodamine-coupled secondary antibodies and counterstaining with 4′,6-diamidino-2-phenylindole to visualize cell nuclei. Images
shown are representative of three different experiments. Original magnification, ×400; bar, 30 nm.
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increasing dosages of IL-1β (with the strongest effect
occurring at 20 ng/ml) and markedly increasing produc-
tion of TNF-β (Figure 2B).
Anti-TNF-β, ASO against NF-κB, curcumin reduce
IL-1β-induced TNF-β-, TNF-α production and NF-κB-
regulated proinflammatory and apoptotic proteins
Because we could demonstrate that IL-1β induces TNF-β
expression in chondrocytes, we next investigated whether
this expression is mediated through the NF-κB signaling
pathway (Figure 3). Whole-cell extracts were evaluated by
Western blot analysis after (1) primary human chon-
drocytes were either left untreated or treated with 10 ng/ml
IL-1β, 5 μM curcumin, 0.5 μM SO control or ASOsagainst NF-κB in the presence of either 10 μl/ml Lipofec-
tin transfection reagent or 10 ng/ml anti-TNF-β for
24 hours; or (2) cells were pretreated with 10 ng/ml IL-1β
for 1 hour followed by cotreatment with 5 μM curcumin,
0.5 μM SO control or ASOs against NF-κB in the presence
of 10 μl/ml Lipofectin transfection reagent or 10 ng/ml
anti-TNF-β for another 24 hours.
IL-1β-induced production of TNF-β and TNF-α is specifically
inhibited by curcumin, ASOs against NF-κB and
anti-TNF-β
Western blot analysis of whole-cell extracts showed spe-
cific inhibition of IL-1β-induced TNF-β as well as TNF-α
production in the presence of ASOs against NF-κB,
demonstrating that the NF-κB signaling pathway plays a
significant role in the production of TNF-β and TNF-α in
Figure 2 IL-1β induces TNF-β protein expression in chondrocytes
in a time- and dose-dependent manner. Primary human
chondrocytes were either treated with 10 ng/ml interleukin 1β (IL-1β)
for the indicated time points (A) or treated with various concentrations
of IL-1β for 1 hour (B). Whole-cell lysates were prepared and analyzed
by Western blotting with antibodies against tumor necrosis factor β
(TNF-β). The results shown are representative of three independent
experiments. Housekeeping protein β-actin served as a loading control
in all experiments.
Figure 3 Effects of antisense oligonucleotides against NF-κB,
curcumin and anti-TNF-β on IL-1β-induced TNF-β expression,
TNF-α expression and NF-κB-regulated proinflammatory and
apoptotic proteins in human chondrocytes. Serum-starved
primary human chondrocytes were (1) either left untreated or treated
with 10 ng/ml interleukin 1β (IL-1β), 5 μM curcumin, 0.5 μM sense
oligonucleotide (SO) control or antisense oligonucleotides (ASOs)
against NF-κB in the presence of Lipofectin transfection reagent
Buhrmann et al. Arthritis Research & Therapy 2013, 15:R202 Page 6 of 14
http://arthritis-research.com/content/15/6/R202chondrocytes (Figure 3A). An SO control had no effect on
TNF-β or TNF-α protein expression. Treatment with the
natural NF-κB inhibitor curcumin also completely inhi-
bited TNF-β and TNF-α production in chondrocytes.
Interestingly, treatment with anti-TNF-β inhibited not
only TNF-β but also TNF-α production, indicating a
possible negative feedback mechanism of TNF-β, which
downregulates TNF-α production.(10 μl/ml) or 10 ng/ml anti-tumor necrosis factor β (anti-TNF-β) alone
for 24 hours; or (2) cells were pretreated with 10 ng/ml IL-1β for 1 hour,
followed by cotreatment with 5 μM curcumin, 0.5 μM SO control or
ASO against nuclear factor κB (NF-κB) in the presence of 10 μl/ml
Lipofectin transfection reagent or 10 ng/ml anti-TNF-β for 24 hours.
Whole-cell extracts were fractionated on SDS-PAGE gels and analyzed
by Western blotting with antibodies against TNF-β and TNF-α (A),
matrix metalloproteinase 9 (MMP-9), MMP-13 and cyclooxygenase 2
(COX-2) (B) and p53 and cleaved caspase 3 (C). Western blots shown
are representative of three independent experiments. Housekeeping
protein β-actin served as a loading control in all experiments.IL-1β-induced, NF-κB-regulated, proinflammatory and
matrix-degrading proteins are inhibited by curcumin, ASOs
against NF-κB and anti-TNF-β
As IL-1β is well-known to upregulate proinflammatory
and matrix-degrading proteins in chondrocytes, all of
which are known to be regulated by NF-κB [43], we next
examined the expression of MMP-9, MMP-13 and Cox-2.
As demonstrated by immunoblotting of total cell lysates,
IL-1β-induced TNF-β production significantly enhances
MMP-9, MMP-13 and Cox-2 production and is com-
pletely blocked in the presence of ASOs against NF-κB or
curcumin (Figure 3B). An SO control had no effect on
MMP-9, MMP-13 and Cox-2 production. Treatment with
anti-TNF-β only partly blocks MMP-9, MMP-13 and
Cox-2 production, indicating that IL-1β-induced inflam-
matory and matrix-degrading signaling is mediated only
in part by TNF-β signaling through the NF-κB pathway.IL-1β-induced NF-κB-dependent expression of apoptotic
proteins is specifically downregulated by curcumin, ASOs
against NF-κB and anti-TNF-β
It is well-known that the NF-κB signaling pathway is in-
volved in cellular apoptosis in chondrocytes [43].Therefore, we next investigated whether blocking
TNF-β inhibits NF-κB-dependent apoptosis. Equal
amounts of total proteins were separated by SDS-
PAGE and analyzed by immunoblotting with anti-
bodies raised against cleaved caspase 3 and p53
(Figure 3C). Transfection with ASOs against NF-κB or
treatment with the natural NF-κB inhibitor curcumin
completely inhibited cleavage of caspase 3 and p53
production. An SO control had no effect on the cleav-
age of caspase 3 and p53 expression. Treatment with
anti-TNF-β also completely blocked cleavage of cas-
pase 3 and p53 production, indicating that TNF-β
might be involved in inducing apoptosis in chondro-
cytes through activation of caspase 3 and p53.
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NF-κB-p65 is inhibited by anti-TNF-β, ASOs against NF-κB
and curcumin
It has been reported that translocation of NF-κB to
the nucleus is necessary for the regulation of gene
expression by NF-κB. The translocation of activated
NF-κB is preceded by phosphorylation of the p65
subunit of NF-κB [44,45]. Therefore, we next inves-
tigated whether IL-1β-induced phosphorylation and
translocation of NF-κB is influenced by TNF-β. (1)
Primary human chondrocytes were either left un-
treated or treated with 10 ng/ml IL-1β, 5 μM curcu-
min, 0.5 μM SO control or ASOs against NF-κB in
the presence of 10 μl/ml Lipofectin transfection re-
agent or 10 ng/ml anti-TNF-β for 24 hours alone; or
(2) cells were pretreated with 10 ng/ml IL-1β for
1 hour followed by cotreatment with 5 μM curcu-
min, 0.5 μM SO control or ASOs against NF-κB in
the presence of 10 μl/ml Lipofectin transfection re-
agent or 10 ng/ml anti-TNF-β for another 24 hours
(Figure 4). Western blot analysis of nuclear extracts
showed that treatment with IL-1β alone or in com-
bination with an SO control significantly induced
NF-κB activation through enhanced p65 transloca-
tion to the nucleus. However, culturing with ASOs
against NF-κB or the natural NF-κB inhibitor curcu-
min completely blocked IL-1β-induced NF-κB-p65
translocation to the nucleus. Furthermore, the SO
control had no inhibitory effect on IL-1β-induced
NF-κB-p65 translocation to the nucleus. Treatment
with anti-TNF-β did not completely block IL-1β-
induced NF-κB-p65 translocation to the nucleus, but
resulted in a significant decrease in translocated
NF-κB-p65 to the nuclear extract (Figure 4).Figure 4 Effects of antisense oligonucleotide against NF-κB, curcu
translocation of NF-κΒ-p65 in nuclear extracts in human chondroc
left untreated or were treated with 10 ng/ml interleukin 1β (IL-1β), 5 μ
sense oligonucleotide (ASO) against nuclear factor κB (NF-κB) in the pr
anti-tumor necrosis factor β (anti-TNF-β) alone for 24 hours; or (2) cells
cotreatment with 5 μM curcumin, 0.5 μM SO control or ASO against N
10 ng/ml anti-TNF-β for 24 hours. Nuclear cell fractions were prepared
phospho-specific p65 and nuclear protein poly(ADP-ribose) polymerase
three independent experiments.Specific ASOs against NF-κB and/or curcumin block
IL-1β-induced nuclear translocation of p65 and suppresses
TNF-β production
On the basis of Western blotting results (Figure 4), and
to examine whether inhibition of NF-κB nuclear trans-
location influences IL-1β-induced TNF-β production
in chondrocytes, we performed immunocytochemical
analysis. Primary human chondrocytes in monolayer
culture (1) were either left untreated or treated for
1 hour with 10 ng/ml IL-1β; (2) were treated with
0.5 μM SO control or ASO against NF-κB in the pre-
sence of Lipofectin transfection reagent for 24 hours; or
(3) were pretreated with the natural NF-κB inhibitor
curcumin (5 μM) for 4 hours followed by cotreatment
with 10 ng/ml IL-1β for 1 hour. Immunolabeling was
then performed with primary antibodies to NF-κB-p65
(Figure 5A) and TNF-β (Figure 5B), followed by incu-
bation with rhodamine-coupled secondary antibodies.
Counterstaining was performed with DAPI to visualize
the cell nuclei. Treatment with IL-1β alone or in combin-
ation with SO control strongly induced NF-κB activation
through enhanced p65 translocation to the nucleus. In
contrast, ASO against NF-κB and curcumin treatment
completely blocked IL-1β-induced p65 nuclear transloca-
tion (Figure 5A), indicating that SO control had no inhibi-
tory effect on p65 translocation to the nucleus.
Treatment with IL-1β alone or IL-1β in combination
with SO control strongly induces TNF-β production in
chondrocytes (Figure 5B). Interestingly, TNF-β pro-
duction is markedly suppressed in cultures treated with
IL-1β and ASO against NF-κB or IL-1β and curcumin,
indicating that, indeed, the activation of NF-κB through
p65 nuclear translocation plays an essential role in
TNF-β production in chondrocytes (Figure 5B).min and anti-TNF-β on IL-1β-induced phosphorylation and
ytes. (1) Serum-starved primary human chondrocytes were either
M curcumin, 0.5 μM sense oligonucleotide (SO) control or anti-
esence of 10 μl/ml Lipofectin transfection reagent or 10 ng/ml
were pretreated with 10 ng/ml IL-1β for 1 hour, followed by
F-κB in the presence of 10 μl/ml Lipofectin transfection reagent or
and examined by Western blot analysis using antibodies against
as a loading control. Western blots shown are representative of
Figure 5 NF-κB-p65 localization and TNF-β expression in human chondrocytes after treatment with IL-1β and/or specific antisense
oligonucleotides against NF-κB or with curcumin. (1) Serum-starved primary human chondrocytes were either left untreated (medium) or
treated for 1 hour with 10 ng/ml interleukin 1β (IL-1β), or (2) cells were pretreated with 10 ng/ml IL-1β for 1 hour followed by cotreatment with
5 μM curcumin (Cur) for 4 hours, transfected with 0.5 μM sense oligonucleotide (SO) control or antisense oligonucleotide (ASO) against NF-κB in
the presence of 10 μl/ml Lipofectin transfection reagent for 24 hours. For immunolabeling, cells were incubated with primary antibodies against
nuclear factor κB (NF-κB)-p65 (A) or tumor necrosis factor β (TNF-β) (B), followed by incubation with rhodamine-coupled secondary antibodies
and counterstaining with 4′,6-diamidino-2-phenylindole to visualize cell nuclei. Images shown are representative of three different experiments.
Original magnification, ×400; bar, 30 nm.
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TNF-β and TNF-β-R are expressed by a variety of cells
including T cells, B cells and NK cells [5]. We per-
formed immunoelectron microscopy [42] to investigate
whether IL-1β treatment enhances TNF-β-R expression
in T lymphocytes. T lymphocytes (Jurkat cells) were
either left untreated (Figure 6B) or treated with 5 ng/ml
IL-1β for 1 hour (Figure 6C). Immunoelectron micro-
scopic images in Figure 6 show low basal expression of
TNF-β-R in T lymphocytes (Figure 6B). Inflammatory
stimulation with IL-1β treatment stimulated T lym-
phocytes to markedly enhance TNF-β-R production
(Figure 6C).
TNF-β induces TNF-β and TNF-β-R expression on surface
of chondrocytes and enhances adhesiveness to T
lymphocytes
As TNF-α is well-known to stimulate its own produc-
tion [46], we next investigated whether, similarly, TNF-βstimulates itself in chondrocytes by enhancing TNF-β and
TNF-β-R production. Primary human chondrocytes were
grown to subconfluence in monolayer culture and either
left untreated or treated with 10 ng/ml IL-1β or with 1, 5
or 50 ng/ml TNF-β for 12 hours. Western blot analysis
demonstrated a marked dose-dependent increase in
TNF-β and TNF-β-R production in chondrocytes as a re-
sult of TNF-β treatment (Figure 7A). Inflammation in RA
is mediated through recruitment of lymphocytes to the
site of inflammation [47]. Therefore, we next performed
an adhesion assay to investigate whether TNF-β-induced
inflammation in chondrocytes actively attracts lym-
phocytes to enhance inflammation in the RA microenvi-
ronment. Primary human chondrocytes were grown to
subconfluence in monolayer culture and treated with 0, 1
or 10 ng/ml TNF-β for 12 hours. Jurkat cells (2 × 106/ml)
were cocultured with chondrocytes and incubated for
4 hours, and the number of T lymphocytes adherent
to the surface of chondrocytes was quantified by light
Figure 6 Immunoelectron microscopic images showing tumor necrosis factor β receptor in T lymphocytes by immunogold labeling.
T lymphocytes were either left untreated without primary antibody (A) or with primary antibody (B) or treated with 5 ng/ml interleukin 1β (IL-1β)
(C). Immunogold labeling (arrows) is detected at the plasma membrane of lymphocytes with antibodies against tumor necrosis factor β receptor.
Images shown are representative of three different experiments. Original magnification, ×25,000; bar, 0.25 μm.
Buhrmann et al. Arthritis Research & Therapy 2013, 15:R202 Page 9 of 14
http://arthritis-research.com/content/15/6/R202microscopy. Treatment with TNF-β did not morphologic-
ally change the chondrocytes. However, stimulation of
chondrocytes with increased dosages of TNF-β resulted in
an almost twofold increase in the adherence of T lympho-
cytes (Figure 7B and 7C), demonstrating the active role
that chondrocytes may play during RA in retaining lym-
phocytes in the joint, thus supporting an inflammatory
milieu and stimulating ongoing inflammation.
Discussion
The goal of this study was to evaluate the potential role
of TNF-β and its receptor in primary human chondro-
cytes and the underlying signaling mechanisms involved
in an in vitro model of an inflammatory environment(Figure 8). The results presented herein led us to the fol-
lowing conclusions: (1) The proinflammatory cytokine
IL-1β induced TNF-β and TNF-β-R expression in chon-
drocytes. (2) Anti-TNF-β suppressed IL-1β-induced
TNF-β and TNF-α expression, which was associated
with the downregulation of NF-κB-dependent, proin-
flammatory proteins (MMPs and Cox-2) and apoptotic
proteins (p53 and cleavage of caspase 3). (3) Knockdown
of NF-κB by mRNA downregulated the expression and ac-
tivation of IL-1β-induced TNF-β in human chondrocytes.
(4) IL-1β-induced NF-κB-p65 phosphorylation, and its
translocation to the nucleus was inhibited by anti-TNF-β,
curcumin or specific ASOs against NF-κB. (5) The adhe-
siveness between TNF-β-expressing T lymphocytes and
Figure 7 Upregulation of TNF-β and TNF-β receptor expression in chondrocytes and adhesiveness of T lymphocytes to chondrocytes
by TNF-β. (A) Serum-starved chondrocytes were grown to subconfluence in monolayer culture and either left untreated (Co) or treated with 10 ng/ml
interleukin 1β (IL-1β) or with 1, 5 or 50 ng/ml tumor necrosis factor β (TNF-β) for 12 hours. Whole-cell lysates were prepared, and samples were
examined by Western blot analysis with antibodies against TNF-β and TNF-β receptor (TNF-βR). Western blots shown are representative of three
independent experiments. The housekeeping protein β-actin served as a loading control. (B) Chondrocytes were grown to subconfluence in
monolayer culture (spindle-shaped to elongated cells) and were either left untreated (Co) or treated with 1 or 10 ng/ml TNF-β for 12 hours,
washed and cocultured with Jurkat cells (round to ovoid cells) for 4 hours. After being washed with phosphate-buffered saline, adhesion of
T lymphocytes (arrows) to chondrocytes was evaluated by light microscopy. Original magnification, ×100; bar, 30 nm. Inset: original magnification,
×400; bar, 3 nm. (C) The number of Jurkat cells adherent to chondrocytes was estimated and quantified by counting ten microscopic fields per culture.
Chondrocytes were either left unstimulated (Co) or stimulated with 1 or 10 ng/ml TNF-β for 12 hours.
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nificantly enhanced in a TNF-β-induced inflammatory
microenvironment.
It is known that TNF-α plays a major multifunctional
role in the pathogenesis of RA and that blocking this
proinflammatory cytokine is an effective therapeutic tar-
get for treating patients with RA. However, a significant
number of RA patients do not respond adequately to
this treatment, become resistant to anti-TNF-α therapies
or experience significant adverse side effects [19,20,48],
indicating the participation of other cytokines in the
pathogenesis of RA. Therefore, additional development
of new, more selective therapeutic targets is needed to
better control inflammation and joint destruction in RA.
Furthermore, several lines of evidence suggest that, inaddition to well-studied cytokines in RA, such as IL-1β,
IL-6 and TNF-α, other proinflammatory cytokines may
be involved [49,50]. Attention has turned especially
toward TNF-β (alias LT-α), another member of the TNF
superfamily [3] and the closest homolog to TNF-α.
Evidence indicates that TNF-β is associated with auto-
immune and inflammatory diseases, and elevated syno-
vial TNF-β levels have been found in RA patients
[21,47,51,52]. It has previously been shown that in vitro
TNF-β induces FLSs to adopt an aggressive phenotype,
proliferate and actively produce proinflammatory cyto-
kines [3]. In addition, anti-TNF-β treatment was found
to significantly improve clinical symptoms in a colla-
gen-induced RA mouse model. Indeed, pateclizumab,
a novel monoclonal antibody targeting TNF-β, has
Figure 8 Schematic showing TNF-β-induced proinflammatory and apoptotic signaling pathways in primary human chondrocytes in
rheumatoid arthritis. Proinflammatory cytokines (interleukin 1β (IL-1β), tumor necrosis factor α (TNF-α) and TNF-β) reach the synovial fluid
through the bloodstream and can directly induce inflammation in chondrocytes, which leads to expression and production of cytokine
receptors such as IL-1β and TNF-β receptors in the chondrocytes. TNF-β-induced inflammatory signaling in chondrocytes is further
enhanced by upregulation of TNF-β production in T and B cells, by direct interaction of T and B cells with the chondrocytes and by autostimulation of
the chondrocytes themselves. Downstream inflammation signaling of TNF-β in chondrocytes involves nuclear factor κB (NF-κB), leading to the
production of proinflammatory mediators (IL-1β, TNF-α, TNF-β and cyclooxygenase 2 (Cox-2)), cartilage matrix degradation (matrix metalloproteinase 9
(MMP-9) and MMP-13) and apoptotic cascades (cleavage of caspase 3 and p53). The natural NF-κB inhibitor curcumin, antisense oligonucleotide
against NF-κB or anti-TNF-β treatment can disrupt the TNF-β-induced inflammatory cycle through inhibition of the NF-κB signaling cascade, thus
offering a promising therapeutic approach for inhibiting TNF-β-induced inflammatory environment in rheumatoid arthritis.
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in the literature described a patient who did not respond
to anti-TNF-α therapy with infliximab, but responded well
to etanercept, a TNFR-2 crystallizable fragment fusion
protein [21]. Because TNFR-2 is a receptor not only for
TNF-α but also for TNF-β, this further indicates that
TNF-β may play a larger role in inducing and/or enhan-
cing RA than previously believed. Despite the advances in
understanding the functional role of TNF-α in RA, little is
known about the participation of TNF-β in this disease
and remains to be elucidated.
We found that untreated primary human chondro-
cytes had very low expression of TNF-β, but that TNF-β
expression in chondrocytes could be significantly in-
duced time- and dose-dependently by treatment with
the proinflammatory cytokine IL-1β. Furthermore, we
have shown that anti-TNF-β treatment completely
inhibited IL-1β-induced TNF-β and TNF-α production
in chondrocytes, indicating a possible negative feedback
mechanism in which, at least in part, TNF-α expression
is regulated by TNF-β. Interestingly, it has been pre-
viously reported that proinflammatory cytokines TNF-α
and TNF-β are strong stimulators of IL-1β [53],indicating that these cytokines are able to induce each
other. These observations suggest that TNF-β, like
IL-1β, may be actively involved in the inflammation and
destruction that occurs in rheumatoid joints. These
considerations led us to examine whether IL-1β induces
the expression of TNF-β in chondrocytes in vitro.
Several lines of evidence suggest that proinflammatory
cytokines (IL-1β and TNF-α) activate the ubiquitous
transcription factor NF-κB, which leads to further proin-
flammatory cytokine expression and thus to further tis-
sue degradation. Activated NF-κB, also in chondrocytes,
is known to be involved in the regulation of several
genes, including by infection, adhesion, cell-cycle, apop-
tosis, survival and inflammatory processes, by activating
IL-1β, TNF-α, IL-6, Cox-2 and MMPs [2,5,37,46,54-58].
TNF-β has been shown to possess very early similar but
less potent inflammatory potential than TNF-α [59];
however, the signaling transduction pathway of TNF-β
has not been explored in chondrocytes. Furthermore,
the natural polyphenol compound curcumin has been
shown to have strong anti-proinflammatory activity and
to be a natural NF-κB inhibitor in various cells, inclu-
ding chondrocytes [26-29]. NF-κB is part of an inactive
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inhibitor of NF-κB, α subunit (IκBα). For activation of
gene transcription, following phosphorylation and ubiqui-
tination, the p65 and p50 subunits dissociate from the
IκBα complex and translocate to the nucleus to bind to
NF-κB recognition sites in the promoter regions [45].
A possible mechanism underlying the inhibition of in-
ducible NF-κB by curcumin (a natural NF-κB inhibitor)
could be its capacity to inhibit the TNF-β signaling path-
ways in chondrocytes. Furthermore, our results demon-
strate that anti-TNF-β inhibits IL-1β-induced NF-κB
activation and its translocation to the nucleus in chondro-
cytes, demonstrating that TNF-β stimulates activation of
NF-κB in chondrocytes upstream of IκBα dissociation,
similarly to the signaling mechanism observed for TNF-α
or lipopolysaccharide in chondrocytes [28,60]. These
observations suggest that the TNF-β pathway may be
involved in IL-1β-induced NF-κB signaling. We also found
that anti-TNF-β, similarly to curcumin or specific ASOs
against NF-κB, inhibits the proapoptotic protein caspase 3
and p53, the matrix-degrading MMPs, as well as the in-
flammatory enzyme Cox-2, that are regulated by NF-κB,
suggesting the involvement of NF-κB in the regulation
of TNF-β-induced proapoptotic and degradative pathways
in cartilage. The inhibition of these proinflammatory
cytokine-specific proteins by ASOs against NF-κB and
anti-TNF-β underlines the similar characteristics that
TNF-α and TNF-β exhibit in chondrocytes. The observa-
tion that TNF-α, a major cytokine present in the rheuma-
toid joints, stimulates the NF-κB signaling pathway has
led to the approval of several TNF-α blockers in RA [5],
and similar considerations might be given to the use of
TNF-β in the future.
We next investigated whether inhibition of NF-κB
activation and its nuclear translocation influenced IL-1β-
induced TNF-β production in chondrocytes. Previously,
our group has shown that, in the human myelo-
monoblastic leukemic cell line ML-1a, both TNF-α and
TNF-β induce activation of NF-κB by signaling through
TNF receptor subunits P80 and P60 [61]. In this study,
we have shown that knockdown of NF-κB by ASOs
downregulated the expression and activation of IL-1β-
induced TNF-β in human chondrocytes. These results
suggest that downregulation of TNF-β by NF-κB mRNA
interference abrogates its stimulated effects on NF-κB
and the proteins involved in inflammation and apop-
tosis, thus highlighting the importance of the TNF-β/
NF-κB pathway during RA. To the best of our know-
ledge, this study is the first investigation that describes
the effects of ASOs against NF-κB on TNF-β signaling
pathways in human chondrocytes.
We observed that human chondrocytes express TNF-β
receptors; therefore, further experiments were performed
to determine their responsiveness to stimulation withTNF-β. In the present study, we have demonstrated that
TNF-β treatment markedly induced its own expression in
chondrocytes in a manner comparable to that of TNF-α
[46]. We have further shown that creating an inflamma-
tory microenvironment in chondrocytes through TNF-β
stimulation enhanced the adhesiveness of T lymphocytes
to chondrocytes. Moreover, it is known that NF-κB also
regulates the expression of several genes that encode ad-
hesion molecules such as intercellular adhesion molecule
1, vascular cell adhesion molecule 1 and E-selectin [62]
and that these in turn are responsible for the recruitment
of neutrophils, eosinophils and T lymphocytes from the
circulation to the site of inflammation in chronic inflam-
matory diseases. It is further known that in RA FLSs
actively bind T and B lymphocytes through LTα1β2 and in-
duce the production of proinflammatory chemokines [63].
These results therefore suggest a new role for chondro-
cytes during RA in the retention of lymphocytes in the
joint in supporting an inflammatory milieu and in stimu-
lating ongoing inflammation mediated by TNF-β/NF-κB
signaling.
Conclusions
Our study demonstrates for the first time that TNF-β is
an important regulator in activation of the NF-κB signa-
ling pathway and its regulated proteins involved in in-
flammation, matrix degradation and apoptosis in human
chondrocytes in vitro. We have further shown that TNF-β
treatment stimulated chondrocytes and made them at-
tractive for adhesion of T lymphocytes, indicating a con-
nection between TNF-β signaling in chondrocytes and the
recruitment of T lymphocytes for the upkeep of micro-
environment inflammation in the rheumatoid joint. These
results demonstrate that, during inflammation in chon-
drocytes, TNF-β signals similarly to TNF-α. As many pa-
tients only weakly respond to anti-TNF-α therapy, or even
become resistant to it [19], blocking of TNF-β in com-
bination with other TNF family members may be useful in
the development of future new therapies for the treatment
of inflammatory joint diseases such as RA.
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